| Family: | Virtus ETF Solutions |
| Name: | Virtus LifeSci Biotech Clinical Trials ETF |
| Inception Date: | 17-Dec-2014 |
| Termination Date: | |
| Investment Objective: | Virtus LifeSci Biotech Clinical Trials ETF is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the performance of the LifeSci Biotechnology Clinical Trials Index. Clinical Trials stage companies are typically younger, smaller companies which do not have a drug approved, but instead focus on testing their experimental drugs. |
| Prospectus | |
| Top 10 Holdings | ||
| uniQure NV | QURE | 1.1828% |
| Definium Therapeutics Inc | DFTX | 1.1364% |
| Apogee Therapeutics Inc | APGE | 1.0030% |
| REGENXBIO Inc | RGNX | 0.9994% |
| Monopar Therapeutics Inc | MNPR | 0.9940% |
| Jade Biosciences Inc | JBIO | 0.9531% |
| MBX Biosciences Inc | MBX | 0.9100% |
| Biohaven Ltd | BHVN | 0.8854% |
| Viking Therapeutics Inc | VKTX | 0.8794% |
| 4D Molecular Therapeutics Inc | FDMT | 0.8785% |
| Top 10 Holdings Weight: | 9.8% |
| Number of Holdings: | 132 |
| Shares Outstanding: | 950,004 |
| Total Net Assets: | 47,157,910 |
| NAV: | 49.55 |
| Net Expense Ratio: | 0.65% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
